Please ensure Javascript is enabled for purposes of website accessibility

Why Exactech Skyrocketed 31% Today

By Todd Campbell - Oct 23, 2017 at 5:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A deal with a venture capital firm is sending shares soaring.

What happened

After agreeing to be taken private by global alternative asset manager TPG Capital, Exactech (NASDAQ: EXAC) jumped 31% today.

So what

Exactech makes orthopedic implant devices and related surgical instruments that it markets to hospitals and doctors. Aging baby boomers are increasing the number of orthopedic procedures done every year, and private equity manager TPG thinks it can accelerate market share over time by owning the company outright.

A businessman points at dollar signs that are displayed on a screen in front of him.

IMAGE SOURCE: GETTY IMAGES.

Exactech's founders Dr. Bill Petty and Betty Petty agree. The two founded the company in 1985 and they've committed their shares to back the $625 million deal. Shareholders will receive $42 in cash per share, a 31% premium to last Friday's close.

"As long-term healthcare investors, we aim to identify and partner with strong companies that are in growing, attractive sectors," said Todd Sisitsky, the managing partner at TPG Capital. "With their strong commitment to patients and surgeons and a comprehensive product portfolio, Exactech has strategically built a platform poised for significant growth."

Now what

TPG Capital is no stranger to the orthopedics market. The company was part of a deal that took hip and knee company Biomet private back in 2007 for $11.3 billion. TPG and its partners sold Biomet to Zimmer for $13.35 billion in 2014.

Apparently, TPG thinks it can catch lightning in a bottle again. The biggest players in this market include J&J, Zimmer Biomet, Stryker, and Smith & Nephew, and they represent an estimated 79% of the global joint replacement market. If going private provides Exactech with greater flexibility it can use to carve away at market share, then perhaps TPG can sell Exactech to one of these big players for a nice profit in the future.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$177.51 (0.29%) $0.52
Stryker Corporation Stock Quote
Stryker Corporation
SYK
$198.93 (-0.25%) $0.50
Smith & Nephew plc Stock Quote
Smith & Nephew plc
SNN
$27.92 (-0.64%) $0.18
Zimmer Biomet Holdings, Inc. Stock Quote
Zimmer Biomet Holdings, Inc.
ZBH
$105.06 (-1.40%) $-1.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.